Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
BUSINESS
Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
Sandoz, a generic arm of the Novartis group, will see the NHI reimbursement prices of its generics chopped by an average 20% under the FY2016 drug price revision in April, the largest price cut among six major generic makers that…
To read the full story
Related Article
BUSINESS
- Enhertu Gets Conditional Nod for Lung Cancer in China
October 16, 2024
- Sandoz Japan Gets OK to Add New Manufacturing Site for Anapeine
October 15, 2024
- Lilly CEO Touts Benefits of Early AD Drug Kisunla
October 15, 2024
- Asahi Kasei Offshoot to Develop Cancer Vaccine Using Proprietary DDS Base
October 11, 2024
- Ono Snags Worldwide Rights to LigaChem’s ADC Assets
October 11, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…